A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

NCT02433093 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder, Healthy Volunteer

Interventions

DRUG: Basimglurant
DRUG: Placebo

Sponsor

Hoffmann-La Roche